Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.34

0.0%

Nov 6 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (1096)	11/14/2001 1:22:37 PM
From: Arthur Radley	Read Replies (1) of 1475

Are we getting to the party toooo late? FDA approves Amgen's rheumatoid arthritis drug THOUSAND OAKS, Calif., Nov 14 (Reuters) - Biotech company Amgen Inc. (NasdaqNM:AMGN - news) said on Wednesday U.S. regulators approved its new drug Kineret to treat rheumatoid arthritis, a chronic disease that afflicts about 2.1 million Americans. The firm said the U.S. Food and Drug Administration approved the drug for patients who have failed one or more disease modifying antirheumatic drugs. Kineret, known generically as anakinra, is a genetically engineered version of a natural protein that keeps a substance called interleukin-1 from attaching to cells and causing inflammation. It is given by self-injection under the skin.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next